Literature DB >> 8486569

The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.

D S Reeves1, M J Bywater, H A Holt.   

Abstract

Two thousand eight hundred and fifty-eight aerobic clinical isolates of Enterobacteriaceae, Pseudomonas species, staphylococci, streptococci and Haemophilus species were collected in 19 geographically separated centres in the UK and one in Ireland. The identity of each isolate was confirmed at Southmead Hospital and the MIC of cefpirome, cefotaxime, ceftazidime, cefuroxime, cephradine, amoxycillin, piperacillin, imipenem, gentamicin, ciprofloxacin and trimethoprim was determined by an agar dilution method. Against species of Enterobacteriaceae not associated with producing an inducible cephalosporinase, cefpirome had a similar degree of activity to cefotaxime and was more active than ceftazidime and earlier cephalosporins. Against species with a high prevalence of inducible beta-lactamase production, cefpirome was superior to other cephalosporins; imipenem was also active against these isolates. Cefpirome was active against Pseudomonas aeruginosa, methicillin-sensitive staphylococci, non-enterococcal streptococci and Haemophilus spp. When the isolates were exposed to 0.1 mg/L of imipenem in agar plus the test agent, cefpirome had superior activity compared with the other cephalosporins tested for the Enterobacteriaceae, except Proteus vulgaris and Proteus penneri. 8.7% of Enterobacter spp., 7% of Citrobacter spp. and 6.7% of Morganella morganii had susceptibilities to beta-lactams suggesting constitutive hyperproduction of chromosomal cephalosporinase; cefpirome, unlike the other cephalosporins tested, was active against these isolates, although to a lesser degree than against the wild-type inducible isolates. No isolates were thought to produce an extended-spectrum beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486569     DOI: 10.1093/jac/31.3.345

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose.

Authors:  I R Friedland; E Sultan; K H Lehr; B Lenfant
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

3.  Nosocomial epiglottitis associated with penicillin- and cephalosporin-resistant Streptococcus pneumoniae bacteremia.

Authors:  R S Daum; J P Nachman; C D Leitch; F C Tenover
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

4.  Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.

Authors:  Fred C Tenover; Shannon L Emery; Carol A Spiegel; Patricia A Bradford; Samantha Eells; Andrea Endimiani; Robert A Bonomo; John E McGowan
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

5.  Antibacterial effect of fosfomycin tromethamine on the bacteria inside urinary infection stones.

Authors:  Fei Song; Chuan Liu; Junyong Zhang; Yusheng Lei; Zili Hu
Journal:  Int Urol Nephrol       Date:  2019-12-12       Impact factor: 2.370

6.  Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicemic patients.

Authors:  M G Bergeron; M Bernier
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.